Floatz logo

Asenapine

Major Depressive Disorder Without Psychotic Features

Duke UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

235 Active assets in the Major Depressive Disorder Without Psychotic Features cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
(1S,2R)-MILNACIPRAN
Allergan
Phase 4BBB

View all 50 →

Same molecule, other indications

Asenapine is also rated in:

bipolar disorderDormant
BBB
Indicative ·
77 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →